Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-4066
      • ALG.APV-527
      • HLX22
    • Scientific publications
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Corporate deck
    • Capital raisings
      • Preferential Rights Issue Q4 2025
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
Key downloads
Alligator Bioscience publishes Annual Report for 2025Alligator Bioscience AB reports full year financial results for 2025 and for Q4 2025 and provides a business updateBulletin from the extraordinary general meeting in Alligator Bioscience ABAlligator Bioscience AB reports financial results for Q3 2025 and provides a business updateAlligator Bioscience AB reports financial results for Q2 2025 and provides a business update
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRMARRegulatoryReport
View as grid View as list
2021-11-10

Alligator Bioscience to Participate in Upcoming Investor Conferences

Lund, Sweden, November 10, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Offi ...
Continue reading
2021-11-092022-07-20

Alligator Bioscience publishes prospectus in connection with forthcoming rights issue

  NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HO ...
Continue reading
2021-11-08

Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam

First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer   Lund, Sweden, N ...
Continue reading
2021-11-08

Bulletin from the extraordinary general meeting in Alligator Bioscience AB

Today, on 8 November 2021, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...
Continue reading
2021-11-03

Nomination Committee appointed in respect of AGM 2022 in Alligator Bioscience AB

Lund, Sweden, November 3, 2021– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...
Continue reading
2021-10-22

Alligator enters into agreements on subscription commitments with board members and senior executives

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has previously, subject to approval ...
Continue reading
2021-10-21

Alligator Bioscience AB: Correction regarding MAR marking

The press release as of October 21, 2021 regarding the Interim report January – September 2021 incorrectly contained a so-called MAR marking ...
Continue reading
2021-10-21
Regulatory

Alligator Bioscience AB: Interim report January–September 2021

First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...
Continue reading
2021-10-21

Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc.

Lund, Sweden, October 20, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the Company was notified that t ...
Continue reading

Posts navigation

Older posts
Newer posts
  1. Startpage
  2. News
About Alligator

Alligator, a clinical-stage biotechnology company, develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
  • Glossary
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheeletorget 1
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2024 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all